➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Express Scripts
Dow
Harvard Business School
Merck

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for MK-1775

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug MK-1775?

MK-1775 is an investigational drug.

There have been 26 clinical trials for MK-1775. The most recent clinical trial was a Phase 2 trial, which was initiated on September 4th 2018.

The most common disease conditions in clinical trials are Carcinoma, Adenocarcinoma, and Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AstraZeneca, and Merck Sharp & Dohme Corp.

There are thirteen US patents protecting this investigational drug and one hundred and thirty-two international patents.

Recent Clinical Trials for MK-1775
TitleSponsorPhase
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction CancersNational Cancer Institute (NCI)Phase 1
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR StudyNational Cancer Institute (NCI)Phase 1
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 2

See all MK-1775 clinical trials

Clinical Trial Summary for MK-1775

Top disease conditions for MK-1775
Top clinical trial sponsors for MK-1775

See all MK-1775 clinical trials

US Patents for MK-1775

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MK-1775   Start Trial Methods and compositions for treatment of cancer and autoimmune disease THE JACKSON LABORATORY (Bar Harbor, ME)   Start Trial
MK-1775   Start Trial Systems and methods for treating cancer Dignity Health (San Francisco, CA) The Translational Genomics Research Institute (Phoenix, AZ)   Start Trial
MK-1775   Start Trial Substituted pyrazolo[3,4-d]pyrimidinone derivatives Banyu Pharmaceutical Co., Ltd. (Chiyoda-Ku, Tokyo, JP)   Start Trial
MK-1775   Start Trial Dihydropyrazolopyrimidinone derivatives MSD K.K. (Chiyoda-Ku, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MK-1775

Drugname Country Document Number Estimated Expiration Related US Patent
MK-1775 Australia 2012275841 2031-06-27   Start Trial
MK-1775 Canada 2839451 2031-06-27   Start Trial
MK-1775 China 103765212 2031-06-27   Start Trial
MK-1775 European Patent Office 2724156 2031-06-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Express Scripts
Dow
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.